N/A
Manufactured by Novartis Pharmaceuticals Corporation
13,183 FDA adverse event reports analyzed
Last updated: 2026-04-14
TRAVOPROST is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Novartis Pharmaceuticals Corporation. The most commonly reported adverse reactions for TRAVOPROST include TREATMENT FAILURE, DRUG INEFFECTIVE, OCULAR HYPERAEMIA, EYE IRRITATION, EYE PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TRAVOPROST.
Out of 8,421 classified reports for TRAVOPROST:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 13,183 FDA FAERS reports that mention TRAVOPROST. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include TREATMENT FAILURE, DRUG INEFFECTIVE, OCULAR HYPERAEMIA, EYE IRRITATION, EYE PAIN, INTRAOCULAR PRESSURE INCREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Novartis Pharmaceuticals Corporation in connection with TRAVOPROST. Always verify the specific product and NDC with your pharmacist.